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variant can predict mortality in dialyzed patients. 
ESRD patients with a less frequent glutamine 
variant (rs20541 T carriers) had increased mor‑
tality rates in comparison with IL‑13 arginine 130 
homozygous subjects. This difference was signif‑
icant (HR, 1.28; CI, 1.01–1.63) and independent 
of older age at first dialysis, presence of coronary 
artery disease, and other predictors.
The genetic variants of IL‑13 were studied thor‑
oughly in allergic disorders. This single nucleo‑
tide polymorphism (SNP) was associated with al‑
lergic rhinitis in numerous studies6 and a func‑
tional analysis demonstrated an increased activ‑
ity of the glutamine variant on the IL‑13 recep‑
tor activation, as measured by signal transducer 
and activator of transcription 6 (STAT6) phos‑
phorylation.7 However, functional effects of IL‑13 
on renal disease progression or comorbidities of 
ESRD have been studied only recently. In the an‑
imal model, overexpression of IL‑13 protected 
the kidneys against acute ischemia–reperfusion 
injury and was suggested to be beneficial for kid‑
ney transplant protection.8 However, fibrotic kid‑
neys have massive CD4+ lymphocyte infiltrates 
and adoptive transfer of CD4+ helper lympho‑
cytes accelerated in progression of tubulointer‑
stitial fibrosis mouse model, depending on Th2 
cells secreting IL‑4 and IL‑13.9 Bone marrow‑ 
‑derived precursors of fibroblasts are among tar‑
get cells for IL‑13‑mediated activation. These cells 
contribute to renal fibrosis and respond to IL‑13 
with STAT6 phosphorylation. Moreover, experi‑
mental knockout of STAT6 decreased interstitial 
fibrosis of the kidneys.10 However, the question of 
how IL‑13 can modify the mortality rate in ESRD 
patients whose kidneys were already damaged re‑
quires elucidation. 
In the past, there were some experimental 
studies on the adverse effects of IL‑13 (or other 
TH2‑like cytokines) on the cardiovascular system. 
In vitro, IL‑13 induced apoptosis of human cor‑
onary arterial endothelial cells, an effect which 
was mediated again by STAT6 phosphorylation 
In the current issue of the Polish Archives of In-
ternal Medicine, Świderska et al.1 reports on ge‑
netic variants of certain cytokines and vitamin 
D pathway in dialyzed patients with end‑stage 
renal disease (ESRD). ESRD is a permanent kid‑
ney failure, the endpoint of chronic kidney dis‑
ease (CKD), frequently caused by diabetes mel‑
litus or arterial hypertension but also by other 
nephropathies. Recently, Mills et al.2 estimated 
a global burden of 497 million adults with CKD 
(stages 1 –5), with age‑specific prevalence of stages 
3–4 reaching 15.8% among men and 22.0% among 
women older than 70 years. Mortality rates in pa‑
tients with ESRD, especially those with diabetes, 
are high, approaching 10% per year. 
 Deficiency of active vitamin D was reported to 
be an independent predictor of mortality in dia‑
lyzed patients with diabetes (hazard ratio [HR], 
1.71; 95% confidence interval [CI], 1.21–2.43) dur‑
ing a 3‑year prospective study.3 In another report4 
on the ESRD cohort described by Świderska et al.,1 
the common variants of vitamin D‑binding pro‑
tein (group‑specific component – GC), vitamin D 
receptor, and retinoic‑acid receptor α (RXRα) were 
not associated with the mortality rate in dialyzed 
patients. Because active vitamin D was measured 
in the study subgroup as 25(OH)D in a random‑
ly selected fraction of patients,4 it could be con‑
cluded that vitamin D deficiency was the culprit 
rather than the genetic variants of the vitamin 
pathway. In fact, a more detailed analysis within 
the same ESRD cohort5 revealed that GC rs7041 
TT homozygotes had lower 25(OH)D levels than 
rs7041 GG homozygotes, but no clinical variables 
were associated with this polymorphism. Thus, in 
summary, an environmental factor, namely, ac‑
tive vitamin D deficiency, is an independent pre‑
dictor of mortality in ESRD, while genetic vari‑
ants in the vitamin D pathway have no effect on 
clinical outcomes.
Even more interesting is a novel finding by 
Świderska et al.1 that a common missence in‑
terleukin 13 (IL‑13) arginine 130 to glutamine 
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and accompanied by a decrease in the production 
of vascular endothelial growth factor.11 Howev‑
er, IL‑13 variants were not found to be associ‑
ated with cardiovascular phenotypes. Patients’ 
data reported by Świderska et al.1 did not explain 
how increased activity of the glutamine variant 
translated into comorbidities or causes of death 
in ESRD patients. The analysis of subjects with 
ESRD and diabetes only did not reveal such a risk 
of rs20541.4 Considering a hypothetical link be‑
tween IL‑13, or in general, TH2‑like cytokines and 
increased mortality rate of dialyzed ESRD pa‑
tients, one should remember about a wide spec‑
trum of clinical conditions leading to progression 
of chronic kidney failure, but also about comor‑
bidities including allergic disorders and altered 
drug pharmacokinetics and interactions in dia‑
lyzed patients.
Yet, there is another interesting finding in 
the study by Świderska et al.,1 focused on the vari‑
ant of the gene for IL‑28B (rs1279860). This poly‑
morphism became well known due to its phar‑
macogenetic interaction with dual ribavirin‑in‑
terferon therapy for chronic hepatitis C. IL‑28B, 
also known as interferon‑λ3, has lower expression 
at the presence of viral RNA in the most common 
rs12979860 CC homozygotes. But the cytokine 
level seems sufficient for inducing interferon‑ 
‑stimulated genes responsible for viral clear‑
ance. In our meta‑analysis, Polish patients with 
chronic hepatitis C had increased frequency of 
rs12979860 CT or TT genotypes, suggesting that 
increasing T variant prevalence of SNP was due 
to a spontaneous virus clearance in rs12979860 
CC homozygotes.12 In ESRD patients, rs12979860 
SNP TT homozygotes had an increased mortality 
rate but only if a history of hepatitis B or C virus 
infection was excluded. The cytokine is induced 
by viral infection in many tissues. It remains to 
be established whether overrepresentation of 
rs12979860 TT genotype among ESRD patients 
with coronary artery disease found by Świderska 
et al.1 had an effect on patients’ survival rates be‑
cause no association was present with myocardial 
infarction, one of the main death causes. More‑
over, in a small prospective study, Roed et al.13 
found several markers of coronary artery disease 
elevated in patients with chronic hepatitis C in 
comparison with controls.
In summary, the survival analysis is rather 
a rough method to evaluate contribution of ge‑
netic factors to the outcome of a disease, especial‑
ly if there are many distinct clinical entities lead‑
ing to the same endpoint as in ESRD. The study 
by Świderska et al.1 included more than 1000 pa‑
tients with ESRD; therefore, it had adequate sta‑
tistical power to exclude other candidate genes 
polymorphisms investigated. However, it will 
require more detailed clinical characteristics to 
identify the positive association signals for ESRD 
mortality found in IL13 and IL28B genes.
